Antigen News and Research RSS Feed - Antigen News and Research

EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Genticel provides update on patents granted in the USA and Asia

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate. [More]
Immune system play role in memory impairment associated with chronic epilepsy

Immune system play role in memory impairment associated with chronic epilepsy

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, based on a study published online by PLOS ONE. [More]
Prognostic value of visceral plural invasion limited in part-solid lung cancer

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate. [More]
Iowa researchers develop vaccine to combat dust-mite allergies

Iowa researchers develop vaccine to combat dust-mite allergies

Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body's immune response. [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. [More]
Chemclin's HIV kits for in-vitro qualitative determination of Anti-HIV 1+2

Chemclin's HIV kits for in-vitro qualitative determination of Anti-HIV 1+2

Chemclin's HIV kits are available for in-vitro qualitative determination of Antibody to Human Immunodeficiency Virus Type 1 and Type 2 (Anti-HIV 1+2) and P24 antigen of HIV in human serum or plasma by a sandwich chemiluminescent assay method. [More]
Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Anti-TP

Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Anti-TP

Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Antibody to Treponema Pallidum (Anti-TP) in human serum or plasma by a double - antigen sandwich chemiluminescent assay method. [More]
Epigenetic test helps eliminate unnecessary repeat prostate biopsies

Epigenetic test helps eliminate unnecessary repeat prostate biopsies

More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed. Therefore there is a need to develop diagnostic tests that will help avoid unnecessary repeat biopsies. [More]
Beckman announces national availability of Prostate Health Index

Beckman announces national availability of Prostate Health Index

Beckman Coulter Diagnostics, a global leader in prostate cancer diagnostics, announces national availability of the Prostate Health Index (phi)*, a simple, non‐invasive blood test that is three times more specific in detecting prostate cancer1 than PSA (prostate‐specific antigen). [More]
Sixteen cores better than 12 for prostate cancer detection

Sixteen cores better than 12 for prostate cancer detection

Sixteen-core prostate biopsy has a slightly higher cancer detection rate than 12-core biopsy, but with a similar safety profile and no increased detection of clinically insignificant tumours, study findings show. [More]
Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step closer to the goal of developing the world's first T-cell peptide-based vaccine for heart disease - the number one killer in the nation. [More]
Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital. [More]
Localised inflammation found in eosinophilic otitis media

Localised inflammation found in eosinophilic otitis media

Antigen-specific immunoglobulin E is produced locally in the middle ear mucosa of patients with eosinophilic otitis media, clinical research indicates. [More]
New gene therapy may be effective for fighting fungal infections in cancer patients

New gene therapy may be effective for fighting fungal infections in cancer patients

Sleeping Beauty and fungal infections - not two items one would normally associate together, but for immunocompromised cancer patients they may prove to be a helpful combination. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). [More]
TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG) developing new antiviral cell-based immunotherapies and Biosafe, a Swiss private company, a developer of innovative solutions for cell processing. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]